Back

Single nucleus RNA sequencing of juvenile dermatomyositis skeletal muscle identifies altered angiogenic signaling

Swoboda, C. O.; Forney, C.; Calvo, C.; Lawson, L. P.; Cevik, H.; Thakkar, K.; Treuting, C.; Waggoner, S. N.; Bayart, C.; Schuh, M. P.; Zygmunt, A.; Angeles-Han, S.; Grom, A.; Schulert, G.; Salomonis, N.; Weirauch, M. T.; Millay, D.; Kottyan, L. C.; O'Connor, S. K.

2026-05-07 genomics
10.64898/2026.05.04.721749 bioRxiv
Show abstract

Juvenile dermatomyositis (JDM) is a chronic multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of complications such as calcinosis cutis, skin ulceration, and mortality. Molecular insight from diagnostic muscle biopsy histology is limited, and the mechanistic pathoetiology of JDM remains poorly defined. We used single nuclei transcriptomics to assess muscle samples from patients with newly diagnosed treatment-naive JDM. As a control, we assessed muscle samples from patients with congenital (nemaline) myopathy (CM), a non-inflammatory disorder. A total of 25,794 high quality nuclei were analyzed and clustered into various muscle-resident or infiltrating cellular populations. JDM tissue was characterized by an enriched interferon (IFN) response signature across endothelial, stromal, and immune cell compartments. Endothelial and perivascular populations showed increased inflammatory and angiogenic programs. Intercellular communication inference analysis identified dysregulated vascular endothelial growth factor (VEGF)-related signaling involving endothelial, stromal, and myonuclear populations as a possible mechanism for myonuclear-driven modulation of the muscle microvasculature. Spatial RNA in situ hybridization supported increased expression of selected IFN responsive and angiogenesis signaling genes in JDM tissue. Collectively, these data provide a cell type-resolved view of treatment-naive JDM muscle and highlight vascular and IFN pathways for follow-up in larger cohorts.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Science Translational Medicine
111 papers in training set
Top 0.1%
33.9%
2
JCI Insight
241 papers in training set
Top 0.1%
18.0%
50% of probability mass above
3
Journal of Clinical Investigation
164 papers in training set
Top 0.6%
4.4%
4
Nature Communications
4913 papers in training set
Top 35%
4.4%
5
Arthritis & Rheumatology
33 papers in training set
Top 0.2%
3.2%
6
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.3%
2.7%
7
The American Journal of Human Genetics
206 papers in training set
Top 2%
1.7%
8
Genome Medicine
154 papers in training set
Top 4%
1.7%
9
eLife
5422 papers in training set
Top 40%
1.7%
10
Cell Reports
1338 papers in training set
Top 24%
1.7%
11
Cell Reports Medicine
140 papers in training set
Top 5%
1.4%
12
Scientific Reports
3102 papers in training set
Top 68%
1.0%
13
Molecular Therapy
71 papers in training set
Top 2%
1.0%
14
Human Molecular Genetics
130 papers in training set
Top 3%
0.9%
15
EMBO Molecular Medicine
85 papers in training set
Top 3%
0.9%
16
Science
429 papers in training set
Top 19%
0.8%
17
Science Advances
1098 papers in training set
Top 28%
0.8%
18
Communications Biology
886 papers in training set
Top 20%
0.8%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
20
Acta Neuropathologica
51 papers in training set
Top 1%
0.8%
21
Cancer Immunology Research
34 papers in training set
Top 0.6%
0.7%
22
Brain
154 papers in training set
Top 5%
0.7%
23
Cell Death & Disease
126 papers in training set
Top 3%
0.7%
24
Acta Neuropathologica Communications
81 papers in training set
Top 1%
0.7%
25
EBioMedicine
39 papers in training set
Top 2%
0.5%
26
Frontiers in Immunology
586 papers in training set
Top 9%
0.5%
27
Frontiers in Genetics
197 papers in training set
Top 12%
0.5%
28
Disease Models & Mechanisms
119 papers in training set
Top 4%
0.5%